Pretreatment synthetic magnetic resonance imaging predicts disease progression in nonmetastatic nasopharyngeal carcinoma after intensity modulation radiation therapy

Insights into Imaging

Table 3 Multivariable analysis for the prediction of PFS in NPC

Parameters	PFS (T1_Kurtosis and clinical factors)		PFS (ADC and clinical factors)
Parameters	HR (95% CI)	p value	HR (95% CI)	p value
T1_Kurtosis	1.093 (1.003, 1.192)	0.043	–	–
ADC	–	–	1.008 (1.002, 1.014)	0.007
Age	1.040 (0.979, 1.192)	0.205	1.053 (0.994, 1.116)	0.078
Sex	1.446 (0.352, 5.937)	0.609	0.905 (0.238, 3.432)	0.883
Treatment	1.021 (0.085, 12.204)	0.987	0.429 (0.031, 5.984)	0.529
T stage	*	0.987	*	0.960
N stage	4.791 (0.484, 47.431)	0.180	1.963 (0.177, 21.820)	0.583
Clinical stage	0.262 (0.032, 2.123)	0.210	1.767 (0.203, 15.349)	0.606

Parameters in bold mean p < 0.05; * indicates the HR and 95% CI were not obtained because there was no disease progression in patients with T1 stage
PFS Progression-free survival; NPC Nasopharyngeal carcinoma; CI Confidence interval; ADC Apparent diffusion coefficient